

Novugen Launches AMVAL Tablets in Singapore

Novugen is proud to announce the launch of AMVAL Film Coated Tablets in Singapore — marking Novugen’s first product launch in the country and another key milestone in our international growth journey.



Approved by the Health Sciences Authority (HSA) on 10 October 2025 through the Abridged Registration Pathway, this achievement is especially meaningful as HSA is among the few regulatory authorities globally recognized by the World Health Organization (WHO) at Maturity Level 4 (ML4), reflecting the highest level of regulatory performance.

AMVAL is indicated for the treatment of essential hypertension. As a combination oral therapy, it supports improved access to treatment while enhancing compliance and adherence for patients managing long-term cardiovascular health.

As the second generic entrant into the Singapore market, this achievement reflects our continued commitment to bringing high-quality, affordable medicines to patients across regulated markets through speed, quality, and regulatory excellence.